Humana said that based on final 2027 Medicare Advantage Star Ratings data (Bonus Year 2028) provided by CMS on October 8, 2026, it exceeded its goal of Top Quartile results, which is defined as Stars revenue PMPM 10% above the peer group median.

1. 01

   Humana said that based on final 2027 Medicare Advantage Star Ratings data (Bonus Year 2028) provided by CMS on October 8, 2026, it exceeded its goal of Top Quartile results, which is defined as Stars revenue PMPM 10% above the peer group median.

2. 02

   The company said it used a consistent 3.0 benchmark of $1,370, a consistent risk score of 1.15, and consistent rebates of $222 for all payers in calculating Stars revenue PMPM, and that actual 2028 values will differ depending on actual membership and contract mix.

3. 03

   Humana said it anticipates some of the outperformance in BY28 relative to Top Quartile will be one-time in nature and expects a benefit for 2028 to be utilized for one-time investments and return to shareholders. It added that it will share the level of and expected use of the one-time benefit on or before the fourth quarter Q4 2027 earnings call when providing detailed 2028 financial guidance.

4. 04

   Humana reaffirmed its guidance of at least $9.00 in adjusted earnings per common share for the year ending December 31, 2026. The company said this guidance is preliminary as it is completing the financial close process for the 3 and 9-month periods ended September 30, 2026 and remains subject to change.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.